{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:30:46Z","timestamp":1761762646941,"version":"3.32.0"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,1,24]],"date-time":"2005-01-24T00:00:00Z","timestamp":1106524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Purpose:<\/jats:bold>\u2002To evaluate the long\u2010term systemic toxicity of tacrolimus (FK\u2010506) administered by various routes, and to assess the effect of dose reduction on toxicity.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>\u2002The study animals were 120 experimentally na\u00efve adult female Wistar rats weighing 200\u2013250\u2003g each. The rats were randomly divided into 10 equal groups (n\u2003=\u200312 in each) and treated with tacrolimus administered topically (in drops, 0.3%, q.i.d.), intravitreally (0.5\u2003mg\/kg bodyweight\/week), intramuscularly (1\u2003mg\/kg bodyweight\/week), low\u2010dose intravenously (1\u2003mg\/kg bodyweight\/week) and in high\u2010dose intravenously (2\u2003mg\/kg bodyweight\/week) for 3\u2003months. The rats in the control groups (one for each different route of administration) were treated with 0.9% NaCl. The blood concentration of tacrolimus, complete blood count and biochemistry parameters were measured each month for the 3\u2010month study period.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>\u2002The rats in the control groups and experimental groups administered topical and intravitreal tacrolimus did not demonstrate any systemic toxic effects. The rats that developed certain toxic effects (hyperglycaemia, hyperkalaemia and nephrotoxicity) in the groups given low\u2010dose or high\u2010dose i.v. tacrolimus responded well to dose reduction. Following dose reduction, blood glucose concentrations decreased from 247.4\u2003\u00b1\u200342.3\u2003mg\/dL to 189.6\u2003\u00b1\u200337.9\u2003mg\/dL (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05), and from 237.4\u2003\u00b1\u200341.1\u2003mg\/dL to 182.3\u2003\u00b1\u200322.7\u2003mg\/dL (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05) in the low\u2010 and high\u2010dose i.v. tacrolimus\u2010treated rats, respectively. The rats that developed impaired hepatic function after high\u2010dose tacrolimus did not respond to dose reduction. Baseline cholesterol concentrations for the intramuscular and low\u2010 and high\u2010dose i.v. tacrolimus\u2010treated groups, demonstrated decreases, respectively, from 87.4\u2003\u00b1\u200314.0\u2003mg\/dL, 86.4\u2003\u00b1\u200314.0\u2003mg\/dL and 90.4\u2003\u00b1\u200314.3\u2003mg\/dL to 53.6\u2003\u00b1\u20039.8\u2003mg\/dL, 52.1\u2003\u00b1\u200312.5\u2003mg\/dL and 63.5\u2003\u00b1\u200311.7\u2003mg\/dL by the end of the second month. The differences were found to be statistically significant (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05 for each result).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>\u2002Topical or intravitreal administration of tacrolimus seems to be systemically safe whereas parenteral administration can cause some systemic haematological changes such as dose\u2010dependent decreased serum cholesterol concentrations. Dose reduction may prevent such adverse effects.<\/jats:p>","DOI":"10.1111\/j.1442-9071.2005.00942.x","type":"journal-article","created":{"date-parts":[[2005,1,24]],"date-time":"2005-01-24T12:43:21Z","timestamp":1106570601000},"page":"53-59","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Systemic toxicity of tacrolimus given by various routes and the response to dose reduction"],"prefix":"10.1111","volume":"33","author":[{"given":"Yusuf","family":"Akar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gultekin","family":"Yucel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali H","family":"Durukan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iclal","family":"Yucel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulbin","family":"Arici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,1,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410273311702"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(92)90111-J"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.104.1.309"},{"key":"e_1_2_6_5_2","first-page":"3328","article-title":"Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum","volume":"23","author":"Abu\u2010Elmagd K","year":"1991","journal-title":"Transplant Proc"},{"key":"e_1_2_6_6_2","first-page":"876","article-title":"Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease","volume":"92","author":"Sandborn WJ","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-26727"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/02713689109013859"},{"key":"e_1_2_6_9_2","first-page":"689","article-title":"Animals in research: religious teachings (The 1995 symposium sponsored by the ARVO Animals in Research Committee)","volume":"37","author":"Stone RA","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.1999.13.2.71"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(02)03510-8"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-199403000-00007"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00168530"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01296817"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709183371203"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2337\/diab.42.12.1753","article-title":"Metabolic effects of cyclosporin A and FK506 in liver transplant recipients","volume":"42","author":"Krentz AJ","year":"1993","journal-title":"Diabetes"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/00007890-199457110-00022","article-title":"Postoperative glucose metabolism in liver transplant recipients: a two\u2010year prospective randomized study of cyclosporine versus FK506","volume":"57","author":"Krentz AJ","year":"1994","journal-title":"Transplantation"},{"key":"e_1_2_6_18_2","first-page":"3148","article-title":"Renal function after conversion from cyclosporine to FK 506 in liver transplant patients","volume":"23","author":"McCauley J","year":"1991","journal-title":"Transplant Proc"},{"key":"e_1_2_6_19_2","first-page":"3146","article-title":"A comparison of the renal effects of FK506 and cyclosporine in patients with liver transplantation","volume":"23","author":"Tauxe WN","year":"1991","journal-title":"Transplant Proc"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199107000-00015"},{"key":"e_1_2_6_21_2","first-page":"753","article-title":"Cytochrome P\u2010450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat","volume":"20","author":"Sattler M","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199801150-00017"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199409000-00006"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.1995.1172"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0022-2275(20)38099-8","article-title":"Alterations in lipoprotein composition associated with galactosamine\u2010induced rat liver injury","volume":"23","author":"Cartwright CK","year":"1982","journal-title":"J Lipid Res"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1982.tb05011.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199407270-00007"},{"key":"e_1_2_6_28_2","first-page":"628","article-title":"Adverse effects of FK 506 overdosage after liver transplantation","volume":"25","author":"Alessiani M","year":"1993","journal-title":"Transplant Proc"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1399-0012.1997.tb00812.x","article-title":"Clinical features of acute reversible tacrolimus (FK506) nephrotoxicity in kidney transplant recipients","volume":"11","author":"Katari SR","year":"1997","journal-title":"Clin Transplant"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199603150-00032"},{"key":"e_1_2_6_31_2","first-page":"3065","article-title":"FK 506 in clinical kidney transplantation","volume":"23","author":"Shapiro R","year":"1991","journal-title":"Transplant Proc"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/02713689109013859"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0012.2003.00028.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3928\/1542-8877-20020301-11","article-title":"Ocular toxicity of intravitreal tacrolimus","volume":"33","author":"Passos E","year":"2002","journal-title":"Ophthalmic Surg Lasers"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-9071.2005.00942.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-9071.2005.00942.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T20:03:21Z","timestamp":1734897801000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-9071.2005.00942.x"}},"subtitle":["Laboratory Science"],"short-title":[],"issued":{"date-parts":[[2005,1,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1111\/j.1442-9071.2005.00942.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-9071.2005.00942.x","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"type":"print","value":"1442-6404"},{"type":"electronic","value":"1442-9071"}],"subject":[],"published":{"date-parts":[[2005,1,24]]},"assertion":[{"value":"2005-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}